10157A081801-NCT04267848OpenTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO StudyThis phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this trial is to find out if the addition of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for non-small cell lung cancer.A081801NCT04267848NationalAdultTreatmentDrug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Other: Observation
Drug: Paclitaxel
Biological: Pembrolizumab
Drug: Pemetrexed Disodium
Other: Quality-of-Life Assessment
Other: Questionnaire AdministrationIIINationalLungThis study investigates the following conditions or diseases: Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Squamous Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8Reuss, JoshuaGeorgetown University Medical Center : Jeanette Crawford; Lombardi Comprehensive Cancer Center : Jeanette Crawford; Medstar Washington Hospital CenterThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); MHRI Washington Cancer Institute; NCA MU NCORP - 6888Jeanette CrawfordJeanette Crawford+1 202-687-0893crawfojg@georgetown.eduResearch Nursing Coordinator
2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>